{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP05212",
    "Peptide Name": "KW13 (AI Predicted AMPs, Lys-rich, UCLL1c, XXA)",
    "Source": "AI predicted, AMP-GPT predicted",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "KWKKWVRAIKKLV",
    "Sequence Length": 13,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 6,
    "Boman Index": 1.4,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "54%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is similar (60%) tosynthetic \nLZ1K: 38%, V=W: 15%.Chemical modification:  C-terminal amidation.Activity:  Active against E. faecalis ATCC 29212 (MIC 16 ug/ml), S. aureus ATCC 29213 (MIC 8 ug/ml), K. pneumoniae ATCC 700603 and 3 resistant strains (MIC 8-32 ug/ml), A. baumannii ATCC 19606 or MDR 316039 (4-8 ug/ml), P. aeruginosa ATCC 27853 or MDR 304238 (MIC 4-8 ug/ml), E. coli ATCC 25922 or MDR 103231 (MIC 4-8 ug/ml).Resistance development:no:bacteria:E. coli ATCC 25922: after 30 multiple passages.In vitro toxicity: not hemo.lytic at 100 ug/ml (HC50>100 ug/ml).half-life in vitro:plasma:human: > 4 h.Animal model:mouse: XDR K. pneumoniae 325016 infected pneumonia mouse model, neutropenic mice, intratracheal i.t./i.p. (2,12h), 99% bacterial reduction (~2 log) in lung treated at 10 mg/kg at 2 and 12 h postinfection.",
    "Author": "Wang J, Feng J, Kang Y, Pan P, Ge J, Wang Y, Wang M, Wu Z, Zhang X, Yu J, Zhang X, Wang T, Wen L, Yan G, Deng Y, Shi H, Hsieh CY, Jiang Z, Hou T. 2025",
    "Reference": "Sci Adv. 2025 Mar 7;11(10):eads8932. doi: 10.1126/sciadv.ads8932.PubMed",
    "Title": "Discovery of antimicrobial peptides with notable antibacterial potency by an LLM-based foundation model."
  },
  "3D Structure": []
}